Oxurion (Euronext Brussels: OXUR - formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.

Biotechnology

Oxurion

Grace Chang

Andy De Deene

Kathleen Paisley

Linda Knott

An Huysmans

Philippe B.

Alfred Aronson

The Medical and Scientific Team at Oxurion is dedicated to advancing the company's portfolio of vision-preserving therapies through rigorous research and clinical development. They collaborate on scientific investigations, support strategic medical communications, and ensure the safe and effective application of treatments for ocular diseases. This team plays a critical role in optimizing drug development processes, engaging with healthcare professionals, and translating complex scientific concepts into actionable insights.

Medical and Scientific Team

Leadership Team

Corporate Governance

Medical and Scientific Team

About

Team members

Other teams at Oxurion

Leadership Team

Corporate Governance